Updated on 2026/01/26

写真a

 
MIYANAGA Sunao
 
Organization
University Hospital, Medical and Dental Sciences Area University Hospital Clinical Center Cardiovascular Center Assistant Professor
Title
Assistant Professor

Degree

  • 博士（医学） ( 2019.7   鹿児島大学 )

Research Areas

  • Life Science / Cardiology  / 肺循環

  • Life Science / Cardiology  / 循環器学

  • Life Science / Cardiology  / 循環器学

  • Life Science / Cardiology  / 肺循環

Professional Memberships

  • 日本内科学会

  • 日本循環器学会

  • 日本肺高血圧・肺循環学会

  • 日本心血管インターベンション治療学会

  • 日本心臓リハビリテーション学会

  • 日本肺高血圧・肺循環学会

  • 日本心血管インターベンション治療学会

  • 日本心臓リハビリテーション学会

  • 日本循環器学会

  • 日本内科学会

▼display all

Qualification acquired

  • 日本内科学会　総合内科専門医

  • 日本内科学会　指導医

  • 日本循環器学会　専門医

 

Papers

  • Mitsuyoshi K., Kubota K., Miyanaga S., Akao M., Ohishi M. .  Association of peak expiratory flow rate with clinical outcomes in pulmonary arterial hypertension .  Hypertension Research   2026

    　More details

    Language：Japanese   Publisher：Hypertension Research  

    Pulmonary arterial hypertension (PAH) is a rare disease characterized by a progressive increase in pulmonary arterial pressure, leading to right heart failure. In clinical practice, reduced exercise tolerance is commonly observed in patients with PAH. Several studies have identified skeletal muscle abnormalities and muscle weakness as factors contributing to impaired exercise capacity in these patients. Recently, peak expiratory flow rate (PEFR) has been shown to correlate with skeletal muscle mass. Given that PEFR can be easily and noninvasively measured using respiratory function tests, we investigated the relationship between PEFR and prognosis in patients with PAH. We enrolled consecutive untreated patients diagnosed with PAH at Kagoshima University Hospital between July 2005 and July 2024. A total of 85 patients were included and divided into the preserved PEFR group and the reduced PEFR group. There were no significant differences in hemodynamic parameters between the two groups; however, the 6-minute walk distance was significantly shorter (p = 0.0062) in the reduced PEFR group. Kaplan–Meier analysis revealed that the cumulative event-free rate was significantly lower in the reduced PEFR group (Log-rank p = 0.0048). Reduced PEFR was independently associated with poorer outcomes after adjusting for age, plus each of right atrial pressure, cardiac index, and pulmonary vascular resistance. In conclusion, PEFR, a method for measuring skeletal muscle, was associated with poor prognosis in patients with PAH when assessed at the time of diagnosis. PEFR can be easily and repeatedly measured, making it potentially useful for prognostic prediction and exercise rehabilitation in these patients. (Figure presented.)

    DOI： 10.1038/s41440-025-02511-6

    Scopus

    PubMed

  • Beppu Risa, Kubota Kayoko, Iwatani Noriko, Miyanaga Sunao, Kirishima Mari, Tanimoto Akihide, Ohishi Mitsuru .  Pulmonary tumor thrombotic microangiopathy associated with endometrial carcinoma: A case report(タイトル和訳中) .  Journal of Cardiology Cases32 ( 4 ) 160 - 162   2025.10

    　More details

    Language：English   Publisher：(一社)日本心臓病学会  

  • Shimokawahara H, Nishizaki M, Inami T, Kubota K, Taniguchi Y, Miyagi A, Kikuchi H, Goda A, Miyanaga S, Hashimoto H, Saito AM, Sekimizu M, Matsubara H. .  Effect of riociguat on exercise following balloon pulmonary angioplasty in patients with inoperable chronic thromboembolic pulmonary hypertension in Japan (THERAPY-HYBRID-BPA): a multicentre, double-blind, randomised, controlled, phase 4 trial .  Lancet Respir Med.13 ( 9 ) 789 - 799   2025.7Reviewed

    　More details

    Language：Japanese   Publisher：Lancet Respiratory Medicine  

    Background: Balloon pulmonary angioplasty (BPA) and medical therapy are the most common treatment options for inoperable chronic thromboembolic pulmonary hypertension (CTEPH), but their combined use has not been sufficiently studied. This study aimed to evaluate the efficacy during an exercise test and the safety of the continuation of riociguat post-BPA in patients with inoperable CTEPH and normalised haemodynamic variables. Methods: This multicentre, double-blind, randomised, controlled, phase 4 trial was conducted at four high-volume CTEPH centres in Japan. Patients aged 18–85 years with a confirmed diagnosis of inoperable, WHO functional class II–IV CTEPH, and a resting mean pulmonary arterial pressure (mPAP) of 25 mm Hg or higher and pulmonary vascular resistance of 3·0 Wood units or higher on right-heart catheterisation, received riociguat and BPA at screening. Screened patients with a resting cardiac index of less than 5·0 L/min per m<sup>2</sup> and mPAP of less than 25 mm Hg 3 months after the final BPA procedure were randomly assigned (1:1) either to receive placebo three times daily for 16 weeks or to continue taking riociguat three times daily for 16 weeks at a dose established during the screening period, which varied per patient from 1·0 mg to 2·5 mg. Randomisation was done via an online system with a block size of 8 based on the allocation factors of medical institution and riociguat dose at allocation; patients and investigators were masked to treatment assignment. The primary endpoint was the change in peak cardiac index calculated using the direct Fick method during a cardiopulmonary exercise test (CPET) from baseline to week 16, and was measured in the full analysis set (ie, all randomly assigned patients apart from those who had withdrawn consent, had severe protocol violations, or had never taken the active drug or placebo) in all patients with available data. The safety analysis included all patients who had taken at least one dose of the active drug or placebo. The trial was registered with the Japan Registry of Clinical Trials (jRCTs041200052) and ClinicalTrials.gov (NCT04600492) and is now closed. Findings: Between Nov 25, 2020, and May 16, 2023, 74 patients (including 58 female patients and 16 male patients) were enrolled and randomly assigned, 36 to the riociguat-discontinuing group and 38 to the riociguat-continuing group. 32 patients in the riociguat-discontinuing group and 34 in the riociguat-continuing group were included in the primary analysis after exclusion of patients with missing data. The adjusted mean of peak cardiac index during CPET changed from baseline to week 16 by −1·11 L/min per m<sup>2</sup> (95% CI −2·14 to −0·09) in the riociguat-discontinuing group and by −0·03 L/min per m<sup>2</sup> (−1·04 to 0·99) in the riociguat-continuing group (intergroup difference 1·09 L/min per m<sup>2</sup> [95% CI 0·20–1·97]; p=0·017). Non-serious adverse events occurred in ten (28%) patients in the riociguat-discontinuing group and 14 (38%) patients in the riociguat-continuing group (p=0·36). No deaths were observed. Interpretation: Our findings suggested that the continuation of riociguat post-BPA might attenuate the worsening of exercise intolerance without increasing the risk of adverse events; discontinuation might require more careful consideration. These results should be explored in long-term studies. Funding: Bayer Yakuhin, Bayer, and Merck Sharp & Dohme.

    DOI： 10.1016/S2213-2600(25)00127-4

    Scopus

    PubMed

  • Akao M., Kubota K., Miyanaga S., Mitsuyoshi K., Ohishi M. .  A young man diagnosed with chronic thromboembolic pulmonary hypertension after COVID-19 infection: A case report .  Journal of Cardiology Cases31 ( 4 ) 121 - 124   2025.4

    　More details

    Language：Japanese   Publisher：Journal of Cardiology Cases  

    Chronic thromboembolic pulmonary hypertension (CTEPH) is a rare disease characterized by pulmonary hypertension (PH), resulting from stenosis or occlusion of the pulmonary arteries owing to an organic thrombus that obstructs blood flow in the pulmonary arteries. The prognosis for untreated patients is poor; however, it has improved significantly with the advent of treatments such as PH-targeted medical therapy and pulmonary balloon angioplasty, in addition to pulmonary endarterectomy. Nevertheless, the exact mechanisms underlying this disease remain unknown. Recently, a close association between coronavirus disease 2019 (COVID-19) and thrombosis has been detected, with the risk of venous thrombosis complications increasing after COVID-19 infection; however, few studies have reported on the association between COVID-19 and CTEPH. Herein, we present the case of a young man who developed CTEPH after a mild COVID-19 infection, despite the lack of an obvious thrombophilic predisposition. We conclude that if a patient develops chronic shortness of breath symptoms after a COVID-19 infection, it is important to investigate not only the COVID-19 sequelae, but also the presence of other diseases such as pulmonary artery thrombosis. Learning objective: Coronavirus disease 2019 (COVID-19) infection frequently causes abnormal blood coagulation and is closely related to thrombosis. Although pulmonary embolism is a frequent complication of venous thrombosis, few studies have reported an association between COVID-19 and chronic thromboembolic pulmonary hypertension (CTEPH). Our patient developed CTEPH after COVID-19 infection. It is important to examine organic abnormalities, before diagnosing persistent dyspnea as a COVID-19 sequela.

    DOI： 10.1016/j.jccase.2025.01.001

    Scopus

    PubMed

  • Akao Mitsumasa, Kubota Kayoko, Miyanaga Sunao, Mitsuyoshi Kokoro, Ohishi Mitsuru .  COVID-19感染後に慢性血栓塞栓性肺高血圧症と診断された若年男性の1例(A young man diagnosed with chronic thromboembolic pulmonary hypertension after COVID-19 infection: A case report) .  Journal of Cardiology Cases31 ( 4 ) 121 - 124   2025.4

    　More details

    Language：English   Publisher：(一社)日本心臓病学会  

    19歳男性。特筆すべき既往はなく、COVID-19ワクチン未接種で2021年5月にCOVID-19に罹患し当院に入院した。当初のCTでは肺動脈や右心に異常所見はなかった。退院後6ヵ月後から呼吸困難が悪化し、失神や下肢浮腫が出現したため2022年1月に当院を受診した。血液検査ではDダイマー高値(3.09pg/mL)を示し、肺シンチグラフィで両肺に多発性欠損を認めた。肺動脈血栓塞栓症と診断し、抗凝固療法を開始した。3ヵ月後のフォローアップ時も呼吸困難が継続していた。6分間歩行距離は335mと短く、心エコーでは右室拡大と右室収縮期圧上昇を認めた。右心カテーテルではPAWP 7mmHg、mPAP 38mmHg、PVR 8.7 WUを、肺シンチグラフィでは換気・血流ミスマッチを、肺動脈造影では両側肺動脈に多数のwebやslit病変を、それぞれ確認した。以上より、慢性血栓塞栓性肺高血圧症(CTEPH)と診断した。リオシグアト導入後、経皮的肺動脈形成術を施行した結果、循環動態は改善した。6分間歩行距離は457mに延伸し、呼吸困難や心電図異常も改善した。

  • 光吉 こころ, 宮永 直, 窪田 佳代子, 大石 充 .  病理解剖にて特発性多中心性キャッスルマン病と診断した重症肺高血圧症の一例 .  日本心臓病学会学術集会抄録72回   C - 2   2024.9

    　More details

    Language：Japanese   Publisher：(一社)日本心臓病学会  

  • Kubota K., Miyanaga S., Akao M., Mitsuyoshi K., Iwatani N., Higo K., Ohishi M. .  Association of delayed diagnosis of pulmonary arterial hypertension with its prognosis .  Journal of Cardiology83 ( 6 ) 365 - 370   2024.6

    　More details

    Language：Japanese   Publisher：Journal of Cardiology  

    Background: Currently, pulmonary hypertension-targeted therapy has been shown to improve the survival of patients with pulmonary artery hypertension (PAH). However, the importance of early diagnosis has not been investigated. Therefore, this study aimed to investigate whether a delayed diagnosis of PAH is associated with its prognosis. Methods and results: A total of 66 consecutive untreated patients were diagnosed with PAH from January 2008 to December 2021 at the Kagoshima University Hospital. The time from symptom onset to diagnosis correlated with brain natriuretic peptide levels (p < 0.001), right ventricle (RV) Tei index (p < 0.001), and the tricuspid annular plane systolic excursion/systolic pulmonary artery pressure ratio (p = 0.003). These findings suggest that in patients with PAH, RV function declines with increasing time from symptom onset to diagnosis. Furthermore, older patients with PAH appeared to have a longer time from symptom onset to diagnosis. Next, patients were divided into delayed diagnosis (>3 months) and early diagnosis (≤3 months) groups based on the time from symptom onset to diagnosis. Patients were categorized into three groups according to the European Society of Cardiology (or the European Respiratory Society) risk stratification guidelines. Patients diagnosed with PAH within 3 months of symptom onset were significantly in the low- or intermediate-risk groups (p < 0.001). A Kaplan-Meier analysis revealed that the cumulative event-free rate was significantly lower (p < 0.01) in the delayed diagnosis group than in the early diagnosis group. A delayed diagnosis was significantly associated with a worse outcome than an early diagnosis, after adjusting for different sets of confounding factors. Conclusions: A delayed PAH diagnosis is associated with a poor prognosis. Early diagnosis of PAH may lead to a low-risk treatment. Furthermore, older patients need more careful screening for PAH.

    DOI： 10.1016/j.jjcc.2023.08.004

    Scopus

    PubMed

  • Kubota Kayoko, Miyanaga Sunao, Akao Mitsumasa, Mitsuyoshi Kokoro, Iwatani Noriko, Higo Kenjuro, Ohishi Mitsuru .  肺動脈性肺高血圧症の診断遅延と予後との関連(Association of delayed diagnosis of pulmonary arterial hypertension with its prognosis) .  Journal of Cardiology83 ( 5-6 ) 365 - 370   2024.6

    　More details

    Language：English   Publisher：(一社)日本心臓病学会  

    肺動脈性肺高血圧症(PAH)の診断遅延が予後と関連するかについて検討するため、2008年1月～2021年12月に当院でPAHと診断された未治療患者を後ろ向きに調べた。患者をリスク層別化基準に従って低、中、高リスクの3群に分類した。全患者は診断後に至適薬物治療を受けた。追跡期間中の全死因死亡とPAHによる再入院を評価した。患者66例(平均54±15歳、女性87.9%)を解析した。症状発症から診断までの時間は、脳ナトリウム利尿ペプチド値(p<0.001)、右室Tei index(p<0.001)、三尖弁輪の収縮期変動/収縮期肺動脈圧比(p=0.003)と相関し、症状発症から診断までの時間の増加に伴い右室機能が低下することが示唆された。症状発症から診断までの時間と年齢にも弱い相関が認められた。症状発症から診断までの時間が3ヵ月超であった患者(診断遅延群)と3ヵ月以下であった患者(早期診断群)では、リスク層別化に有意差がみられ(p<0.001)、高リスク群は診断遅延群の12%、早期診断群の34%であった。カプランマイヤー解析で、診断遅延群の累積無イベント率は早期診断群より有意に低かった(p<0.01)。交絡因子調整後、診断遅延は予後不良と有意に関連した。以上より、PAHの診断遅延は予後不良につながり、特に高齢患者ではより慎重なPAHのスクリーニングが必要と考えられた。

  • 赤尾 光優, 光吉 こころ, 宮永 直, 窪田 佳代子, 大石 充 .  ポナチニブ誘発性の肺高血圧による血行動態不全に対しPCPSを含む集中治療が有効であった1例(A Case of Hemodynamic Failure Due to Ponatinib-induced Pulmonary Hypertension Treated with Intensive Care, Including PCPS) .  日本循環器学会学術集会抄録集88回   CRDJ03 - 7   2024.3

    　More details

    Language：English   Publisher：(一社)日本循環器学会  

  • 赤尾 光優, 光吉 こころ, 宮永 直, 窪田 佳代子, 大石 充 .  COVID-19罹患後に若年で慢性血栓塞栓性肺高血圧症と診断された一例 .  日本心臓病学会学術集会抄録71回   P - 27   2023.9

    　More details

    Language：Japanese   Publisher：(一社)日本心臓病学会  

  • Miyanaga S., Kubota K., Iwatani N., Akao M., Mitsuyoshi K., Ohishi M. .  Pulmonary artery hypertension-associated with human immunodeficiency virus infection with attenuated effect of subcutaneous treprostinil injection during long-term observation: A case report .  Journal of Cardiology Cases28 ( 2 ) 72 - 74   2023.8

    　More details

    Language：Japanese   Publisher：Journal of Cardiology Cases  

    Pulmonary artery hypertension associated with human immunodeficiency virus infection (PAH-HIV) is known to be caused by HIV infection. Antiretroviral therapy and PAH-specific drugs improve the prognosis of patients with PAH-HIV, but the pathophysiology of PAH-HIV remains unclear. We report a case of PAH-HIV treated with upfront combination therapy including subcutaneous injection of treprostinil. One year after treatment initiation, the patient's PAH improved significantly. However, it worsened over time due to reduced efficacy of subcutaneous injection of treprostinil. Learning objective: The etiology and pathophysiology of pulmonary artery hypertension associated with human immunodeficiency virus infection (PAH-HIV) remain unclear, and there are few case reports of PAH-HIV in Japan because the HIV prevalence is low. We encountered a case of PAH-HIV in which the efficacy of subcutaneous treprostinil injection was attenuated. It was unclear whether the reduced efficacy was associated with the pathophysiology of PAH-HIV. When PAH control deteriorates, early alteration of medication choice and administration route is important.

    DOI： 10.1016/j.jccase.2023.04.008

    Scopus

    PubMed

  • Miyanaga Sunao, Kubota Kayoko, Iwatani Noriko, Akao Mitsumasa, Mitsuyoshi Kokoro, Ohishi Mitsuru .  長期観察中にトレプロスチニル皮下投与の効果が減弱したヒト免疫不全ウイルス感染症に関連する肺動脈性肺高血圧症　症例報告(Pulmonary artery hypertension-associated with human immunodeficiency virus infection with attenuated effect of subcutaneous treprostinil injection during long-term observation: A case report) .  Journal of Cardiology Cases28 ( 2 ) 72 - 74   2023.8

    　More details

    Language：English   Publisher：(一社)日本心臓病学会  

    症例は41歳男性。単純ヘルペスウイルス網膜炎の発症後に後天性免疫不全症候群と診断された。その後、右眼の視力低下と左眼の重度視力障害を経験し、高活性抗レトロウイルス療法によりHIV-RNA量はコントロールされていた。心エコー検査で右心肥大と三尖弁逆流圧較差(TRPG)が認められ、右心カテーテル検査の所見から肺高血圧症が考えられたため、HIV関連肺動脈性肺高血圧症(PAH)と診断した。抗レトロウイルス療法をドルテグラビルナトリウム、アバカビル硫酸塩、ラミブジンに変更した。マシテンタンとタダラフィルの経口投与によって症状は軽減したが、労作時呼吸困難が再び出現した。トレプロスチニル皮下投与を開始したところ、症状と血行動態は改善した。PAHの診断から3年後、タダラフィルをリオシグアトに変更し、トレプロスチニルを増量した。しかし、診断から5年後に心エコーでTRPG悪化が認められたため入院した。トレプロスチニルを増量しても頭痛や吐き気などの副作用が認められなくなったことから、トレプロスチニルの効果が不十分であることが疑われた。トレプロスチニルを静脈内投与に切り替えたところ、直ちに顔面紅潮、頭痛、嘔気などの副作用が出現し、1週間後に血行動態は改善した。

  • 赤尾 光優, 神田 大輔, 宮永 直, 大石 充 .  経皮的肺動脈形成術後2日目に仮性動脈瘤破裂を呈した一例 .  日本心血管インターベンション治療学会抄録集31回   MP72 - 1   2023.8

    　More details

    Language：English   Publisher：(一社)日本心血管インターベンション治療学会  

  • 赤尾 光優, 宮永 直, 窪田 佳代子, 大石 充 .  CPFE-severe PHに対しupfront combination therapyを行った一例 .  日本肺高血圧・肺循環学会学術集会・日本小児肺循環研究会プログラム・抄録集7回・28回   137 - 137   2022.7

    　More details

    Language：Japanese   Publisher：日本肺高血圧・肺循環学会・日本小児肺循環研究会  

  • Iwatani N, Kubota K, Ikeda Y, Tokushige A, Miyanaga S, Higo K, Ohishi M .  Different characteristics of mitochondrial dynamics-related miRNAs on the hemodynamics of pulmonary artery hypertension and chronic thromboembolic pulmonary hypertension. .  J Cardiol78 ( 1 ) 24 - 30   2021.7Reviewed

  • Iwatani N., Kubota K., Ikeda Y., Tokushige A., Miyanaga S., Higo K., Ohishi M. .  Different characteristics of mitochondrial dynamics-related miRNAs on the hemodynamics of pulmonary artery hypertension and chronic thromboembolic pulmonary hypertension. .  J Cardiol78 ( 1 ) 24 - 30   2021.7Reviewed

  • Kubota K, Miyanaga S, Iwatani N, Higo K, Tokushige A, Ikeda Y, Ohishi M .  Geriatric Nutritional Risk Index is associated with prognosis in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension .  Circ Rep.2 ( 7 ) 372 - 377   2020.6Reviewed

  • Miyanaga S, Kubota K, Iwatani N, Higo K, Miyata M, Horizoe Y, Ojima S, Kawasoe S, Kubozono T, Ohishi M .  Predictors of exercise-induced pulmonary hypertension in patients with connective tissue disease .  Heart Vessels34 ( 9 ) 1509 - 1518   2019.9Reviewed

  • Higo K, Kubota K, Miyanaga S, Miyata M, Nakajo M, Jinguji M, Ohishi M .  Impairment of iodine-123-metaiodobenzylguanidine (123I-MIBG) uptake in patients with pulmonary artery hypertension .  Int Heart J.59 ( 1 ) 112 - 119   2018.1Reviewed

▼display all

MISC

  • Pulmonary tumor thrombotic microangiopathy associated with endometrial carcinoma: A case report Reviewed

    Beppu R, Kubota K, Iwatani N, Miyanaga S, Kirishima M, Tanimoto A, Ohishi M

    J Cardiol Cases.   32 ( 4 )   160 - 162   2025.6

    　More details

    Language：Japanese   Publisher：Journal of Cardiology Cases  

    Pulmonary tumor thrombotic microangiopathy (PTTM) is a rapidly progressive fatal cancer-related complication. Diagnosing PTTM is challenging, with most cases diagnosed postmortem. Gastric, breast, and lung cancers are the most common primary tumors associated with PTTM. To the best of our knowledge, this is the first case report of PTTM arising from an endometrial carcinoma. A patient with advanced respiratory failure and pulmonary hypertension was diagnosed with endometrial carcinoma. This case highlights the importance of suspecting PTTM in patients with pulmonary hypertension accompanied by rapidly progressive dyspnea when pulmonary embolism has been excluded. In such cases, identifying the primary cancer is crucial for establishing an appropriate treatment plan. It also emphasizes the importance of investigating systemic cancers, extending beyond the frequently encountered cancers, even in the absence of active cancer. Learning objective: Pulmonary tumor thrombotic microangiopathy (PTTM) is a rapidly fatal complication of cancer. This is the first case report of PTTM arising from an endometrial carcinoma. Clinicians should consider PTTM in patients with respiratory failure and pulmonary hypertension, even in the absence of active cancer. Early investigation for underlying malignancy and prompt pathological evaluation are essential for the rapid diagnosis of PTTM.

    DOI： 10.1016/j.jccase.2025.06.013

    Scopus

    PubMed

  • A young man diagnosed with chronic thromboembolic pulmonary hypertension after COVID-19 infection: A case report Reviewed

    Akao M, Kubota K, Miyanaga S, Mitsuyoshi K, Ohishi M

    J Cardiol Cases .   31 ( 4 )   121 - 124   2025.1

    　More details

  • A young man diagnosed with chronic thromboembolic pulmonary hypertension after COVID-19 infection: A case report Reviewed

    Akao M, Kubota K, Miyanaga S, Mitsuyoshi K, Ohishi M

    J Cardiol Cases .   31 ( 4 )   121 - 124   2025.1

    　More details

  • Pulmonary artery hypertension-associated with human immunodeficiency virus infection with attenuated effect of subcutaneous treprostinil injection during long-term observation: A case report Reviewed

    Miyanaga S, Kubota K, Iwatani N, Akao M, Mitsuyoshi K, Ohishi M.

    J Cardiol Cases.   28 ( 0 )   72 - 74   2023.6

    　More details

    Authorship：Lead author   Language：English  

    DOI： 10.1016/j.jccase.2023.04.008.

  • Unknown atrial septal defect was diagnosed during the course of treatment for portopulmonary hypertension: a case report. Reviewed

    Kubota K, Miyanaga S, Iwatani N, Ohishi M

    J Cardiol Cases   26 ( 5 )   383 - 385   2022

  • Unknown atrial septal defect was diagnosed during the course of treatment for portopulmonary hypertension: a case report. Reviewed

    Kubota K., Miyanaga S., Iwatani N., Ohishi M.

    J Cardiol Cases   26 ( 5 )   383 - 385   2022

▼display all

Presentations

  • 赤尾光優, 光吉こころ, 宮永　直, 窪田佳代子, 大石　充.   COVID-19罹患後に若年で慢性血栓塞栓性肺高血圧症と診断された一例.  

    第71回 日本心臓病学会学術集会  2023.9 

    　More details

    Event date： 2023.9

    Venue：東京  

  • 赤尾光優, 光吉こころ, 宮永 直, 窪田佳代子, 大石 充   COVID-19罹患後に若年で慢性血栓塞栓性肺高血圧症と診断された一例.  

    第71回 日本心臓病学会学術集会  2023.9 

    　More details

    Event date： 2023.9

    Venue：東京  

  • 赤尾光優, 神田大輔, 宮永　直, 大石　充   経皮的肺動脈形成術後2日目に仮性動脈瘤破裂を呈した一例.  

    第31回 日本心血管インターベンション治療学会学術集会  2023.8 

    　More details

    Event date： 2023.8

    Venue：福岡市  

  • 赤尾光優, 神田大輔, 宮永 直, 大石 充   経皮的肺動脈形成術後2日目に仮性動脈瘤破裂を呈した一例.  

    第31回 日本心血管インターベンション治療学会学術集会  2023.8 

    　More details

    Event date： 2023.8

    Venue：福岡市  

  • 木原彩貴, 窪田佳代子, 赤尾光優, 光吉こころ, 宮永　直, 大石　充   社会的障壁を有した特発性肺動脈性肺高血圧症の一例.  

    第134回 日本循環器学会九州地方会  2023.6 

    　More details

    Event date： 2023.6

    Venue：熊本市  

  • 光吉こころ, 赤尾光優, 宮永　直, 窪田佳代子, 大石　充, 上田英昭, 曽我欣治.   急性肺塞栓症治療中に卵円孔開存に嵌頓した巨大血栓を認め, 緊急手術にて動脈塞栓症を回避し得た一例.  

    第134回 日本循環器学会九州地方会  2023.6 

    　More details

    Event date： 2023.6

    Venue：熊本市  

  • 光吉こころ, 赤尾光優, 宮永 直, 窪田佳代子, 大石 充, 上田英昭, 曽我欣治   急性肺塞栓症治療中に卵円孔開存に嵌頓した巨大血栓を認め, 緊急手術にて動脈塞栓症を回避し得た一例.  

    第134回 日本循環器学会九州地方会  2023.6 

    　More details

    Event date： 2023.6

    Venue：熊本市  

  • 木原彩貴, 窪田佳代子, 赤尾光優, 光吉こころ, 宮永 直, 大石 充   社会的障壁を有した特発性肺動脈性肺高血圧症の一例.  

    第134回 日本循環器学会九州地方会  2023.6 

    　More details

    Event date： 2023.6

    Venue：熊本市  

  • Akao M, Mitsuyoshi K, Miyanaga S, Kubota K, Ohishi M   Association of delayed pulmonary arterial hypertension diagnosis with prognostic predictor  

    2023.3 

    　More details

    Event date： 2023.3

  • Akao M., Mitsuyoshi K., Miyanaga S., Kubota K., Ohishi M.   Association of delayed pulmonary arterial hypertension diagnosis with prognostic predictor  

    2023.3 

    　More details

    Event date： 2023.3

  • 木原悠起, 赤尾光優, 光吉こころ, 宮永　直, 窪田佳代子, 大石　充   部分肺静脈還流異常症に伴う肺動脈性肺高血圧症に対しTreat and Repairを実施した一症例.  

    第133回 日本循環器学会九州地方会  2022.12 

    　More details

    Event date： 2022.12

    Venue：久留米市  

  • 木原悠起, 赤尾光優, 光吉こころ, 宮永 直, 窪田佳代子, 大石 充   部分肺静脈還流異常症に伴う肺動脈性肺高血圧症に対しTreat and Repairを実施した一症例.  

    第133回 日本循環器学会九州地方会  2022.12 

    　More details

    Event date： 2022.12

    Venue：久留米市  

  • 赤尾光優, 宮永　直, 窪田佳代子, 大石　充   肺動脈性肺高血圧症における早期診断の有用性についての検討.  

    第70回 日本心臓病学会学術集会  2022.9 

    　More details

    Event date： 2022.9

  • 赤尾光優, 宮永 直, 窪田佳代子, 大石 充   肺動脈性肺高血圧症における早期診断の有用性についての検討.  

    第70回 日本心臓病学会学術集会  2022.9 

    　More details

    Event date： 2022.9

  • 赤尾光優, 光吉こころ, 宮永　直, 窪田佳代子, 大石　充   CPFE-severe PHに対しupfront combination therapyを行った一例.  

    第7回 日本肺高血圧・肺循環学会学術集会  2022.7 

    　More details

    Event date： 2022.7

  • 赤尾光優, 光吉こころ, 宮永 直, 窪田佳代子, 大石 充   CPFE-severe PHに対しupfront combination therapyを行った一例.  

    第7回 日本肺高血圧・肺循環学会学術集会  2022.7 

    　More details

    Event date： 2022.7

  • 宇都宮麻子, 岩谷徳子, 宮永　直, 窪田佳代子, 大石　充   シェーグレン症候群の味覚異常によりるいそうを来した一例.  

    医学生・研修医の日本内科学会ことはじめ　2022　京都  2022.4 

    　More details

    Event date： 2022.4

    Venue：京都市  

  • 宇都宮麻子, 岩谷徳子, 宮永 直, 窪田佳代子, 大石 充   シェーグレン症候群の味覚異常によりるいそうを来した一例.  

    医学生・研修医の日本内科学会ことはじめ 2022 京都  2022.4 

    　More details

    Event date： 2022.4

    Venue：京都市  

  • 岩谷徳子, 窪田佳代子, 池田義之, 宮永　直, 大石　充   肺動脈性肺高血圧症と慢性血栓塞栓性肺高血圧症におけるミトコンドリアダイナミクス関連miRNA発現の相違  

    第69回 日本心臓病学会学術集会 

    　More details

    Event date： 2021.9

    Venue：鳥取県米子市  

  • 岩谷徳子, 窪田佳代子, 池田義之, 宮永 直, 大石 充   肺動脈性肺高血圧症と慢性血栓塞栓性肺高血圧症におけるミトコンドリアダイナミクス関連miRNA発現の相違  

    第69回 日本心臓病学会学術集会 

    　More details

    Event date： 2021.9

    Venue：鳥取県米子市  

  • 下園夏帆, 宮永　直, 岩谷徳子, 窪田佳代子, 大石　充   臨床症状と画像診断から早期生前診断に至ったPTTMの一例  

    第6回 日本肺高血圧・肺循環学会学術集会 

    　More details

    Event date： 2021.5

    Venue：東京  

  • 下園夏帆, 宮永 直, 岩谷徳子, 窪田佳代子, 大石 充   臨床症状と画像診断から早期生前診断に至ったPTTMの一例  

    第6回 日本肺高血圧・肺循環学会学術集会 

    　More details

    Event date： 2021.5

    Venue：東京  

  • Iwatani N, Kubota K, Ikeda Y, Miyanaga S, Ohishi M   Notable participation of mitochondrial dynamics-related mirna in the pathophysiology of pulmonary hypertension  

    第 85 回 日本循環器学会学術集会 

    　More details

    Event date： 2021.3

    Venue：横浜市  

  • Iwatani N., Kubota K., Ikeda Y., Miyanaga S., Ohishi M.   Notable participation of mitochondrial dynamics-related mirna in the pathophysiology of pulmonary hypertension  

    第 85 回 日本循環器学会学術集会 

    　More details

    Event date： 2021.3

    Venue：横浜市  

  • 岩谷徳子, 宮永　直, 窪田佳代子, 徳重明央, 池田義之, 大石　充   女性研究者奨励賞セッション. Mitochondrial fission-related miRNAs Plays a role in the etiology of pulmonary artery diseases  

    第129回 日本循環器学会九州地方会 

    　More details

    Event date： 2020.12

  • Iwatani N, Kubota K, Ikeda Y, Miyanaga S, Tokushige A, Ohishi M   Mitochondrial fission-related miRNAs plays a role in the etiology of pulmonary artery diseases   International conference

    The American Heart Association’s Scientific Sessions 2020 

    　More details

    Event date： 2020.11

    Venue：Dallas, USA  

  • 林　真生, 宮永　直, 岩谷徳子, 窪田佳代子, 大石　充   肺高血圧症を合併した衝心脚気の一例  

    第5回 日本肺高血圧・肺循環器学会学術集会 

    　More details

    Event date： 2020.9

  • 宮永　直, 岩谷徳子, 窪田佳代子, 大石　充   当院で経験した高齢独居CTEPHの1例  

    第30回 日本老年医学会九州地方会（誌上開催） 

    　More details

    Event date： 2020

  • 伊比隆輔，窪田佳代子，岩谷徳子，宮永　直，大石　充   研修医セッション. 診断時に続発性気胸を併発していたCTEPHの1例  

    第127回 日本循環器学会九州地方会 

    　More details

    Event date： 2019.12

    Venue：久留米市  

  • 宮永　直，岩谷徳子，窪田佳代子，大石　充   Treat and Repairを行った肺高血圧症合併心房中隔欠損症の2例  

    第67回 日本心臓病学会学術集会 

    　More details

    Event date： 2019.9

    Venue：名古屋市  

  • 岩谷徳子，宮永　直，窪田佳代子，大石　充   CTEPHの治療経過中にCVポートの血栓形成を認めた2症例  

    第4回 日本肺高血圧・肺循環器学会学術集会 

    　More details

    Event date： 2019.6

    Venue：浜松市  

  • 中尾周平，宮永　直，岩谷徳子，窪田佳代子   肺移植後に身体活動の長期変化を観察した肺高血圧症患者の1例  

    第4回 日本肺高血圧・肺循環器学会学術集会 

    　More details

    Event date： 2019.6

  • 肥後建樹郎, 窪田佳代子, 宮永　直, 岩谷徳子, 大石　充   PGI2製剤の切り替えが有効であったPAHの一症例  

    第66回 日本心臓病学会学術集会 

    　More details

    Event date： 2018.9

  • 宮永　直, 窪田佳代子, 岩谷徳子, 肥後建樹郎, 宮田昌明, 堀添善尚, 小島聡子, 川添　晋, 窪薗琢郎, 大石　充   YIA臨床研究 (CR) セッション. 膠原病患者における運動誘発性肺高血圧症の非侵襲的予測因子の検討  

    第124回 日本循環器学会九州地方会 

    　More details

    Event date： 2018.6

  • Mean pulmonary arterial pressure at final balloon pulmonary angiop lasty predicts the improvement of exercise capacity after one-year in CTEPH patients   International conference

    ACC 67th Annual Scientific Session 

    　More details

    Event date： 2018.3

    Venue：Orlando, USA  

  • 岩谷徳子, 窪田佳代子, 宮永　直, 大石　充   Mean pulmonary arterial pressure at final balloon pulmonary angiop lasty predicts the improvement of exercise capacity after one-year in CTEPH patients  

    第82回 日本循環器学会学術集会 

    　More details

    Event date： 2018.3

    Venue：大阪  

  • 沖野秀人, 窪田佳代子, 岩谷徳子, 宮永　直, 大石　充, 浜田平一郎   ダサチニブ使用により遅発性に出現した肺高血圧症の1例  

    日本内科学会 第320回 九州地方会 

    　More details

    Event date： 2018.1

    Venue：福岡  

  • 岩谷徳子, 宮永　直, 窪田佳代子, 大石　充   門脈肺高血圧症の治療経過で心房中隔欠損症が判明した1例  

    第65回 日本心臓病学会学術集会 

    　More details

    Event date： 2017.9

    Venue：大阪  

  • 宮永　直, 岩谷徳子, 窪田佳代子, 大石　充   HIV-related PAHに対してcombination therapyを行った一例  

    第2回 日本肺高血圧・肺循環学会学術集会 

    　More details

    Event date： 2017.6

    Venue：札幌  

  • 町頭郁哉, 窪田佳代子, 岩谷徳子, 宮永　直, 大石　充   側弯症に合併した肺高血圧症の一例  

    日本内科学会 第317回 九州地方会 

    　More details

    Event date： 2017.5

    Venue：沖縄  

  • Miyanaga S, Kubota K, Iwatani N, Higo K, Horizoe Y, Chaen H, Uchiyama N, Ojima S, Kawasoe S, Kubozono T, Miyata M, Ohishi M   Determinants of exercise tolerance after balloon pulmonary angioplasty in patients with chronic thromboembolic pulmonary hypertension   International conference

    AHA Scientific Sessions 2016 

    　More details

    Event date： 2016.11

    Venue：New Orleands, USA  

  • 肥後建樹郎, 窪田佳代子, 宮永　直, 宮田昌明, 大石　充   123I-MIBGシンチを用いた肺高血圧症における肺血管内皮機能検査  

    第64回 日本心臓病学会学術集会 

    　More details

    Event date： 2016.9

    Venue：東京  

  • Higo K, Kubota K, Miyanaga S, Miyata M, Nakajo M, Jinguji M, Ohishi M   Novel diagnostic tool of PAH: lung 123I-MIBG scintigraphy   International conference

    　More details

    Event date： 2016.4

  • Chaen H, Yuasa T, Horizoe Y, Ueya N, Miyanaga S, Kubota K, Mizukami N, Takasaki K, Miyata M, Kisanuki A, Ohishi M   The chronic effect of balloon pulmonary angioplasty on right ventricular function in patients with chronic thromboembolic pulmonary hypertension.  

    　More details

    Event date： 2016.3

  • 岩谷徳子, 窪田佳代子, 宮永　直, 肥後建樹郎, 大石　充.   高齢者難病疾患患者のターミナルケア.  

    第26回 日本老年医学会九州地方会 

    　More details

    Event date： 2016.3

    Venue：鹿児島市  

  • 園田智洋, 桑波田 聡, 辻　紘明, 長友理笑, 迫田　隆, 竹中俊宏, 宮永　直, 岩谷徳子, 窪田佳代子, 安部　智, 大石　充.   右心不全の原因診断に苦慮した1例  

    鹿屋地区内科医会症例検討会 

    　More details

    Event date： 2016.2

  • 宮永　直, 肥後建樹郎, 田中佳代子, 大石　充.   IgG4高値を伴う肺高血圧症にステロイドが有効であった一例.  

    第63回 日本心臓病学会学術集会 

    　More details

    Event date： 2015.9

    Venue：神奈川県  

  • 鮫島光平, 宮永　直, 肥後建樹郎, 窪田佳代子, 大石　充.   褐色細胞腫を伴うEisenmenger症候群に対しBosentan導入を行った1例.  

    第310回 日本内科学会九州地方会 

    　More details

    Event date： 2015.8

  • 肥後建樹郎, 窪田佳代子, 武田綾乃, 宮永　直, 東 美智代, 大石　充.   生前の確定診断後に分子標的薬で加療し救命できたPTTM(Pulmonary Tumor Thrombotic Microangiopathy)の一例  

    第62回 日本心臓病学会学術集会 

    　More details

    Event date： 2014.9

  • 赤尾 光優, 宮永 直, 窪田 佳代子, 大石 充   CPFE-severe PHに対しupfront combination therapyを行った一例  

    日本肺高血圧・肺循環学会学術集会・日本小児肺循環研究会プログラム・抄録集  2022.7  日本肺高血圧・肺循環学会・日本小児肺循環研究会

    　More details

    Language：Japanese  

  • 赤尾 光優, 光吉 こころ, 宮永 直, 窪田 佳代子, 大石 充   肺動脈性肺高血圧症の診断遅延と予後予測因子との関連性(Association of Delayed Pulmonary Arterial Hypertension Diagnosis with Prognostic Predictors)  

    日本循環器学会学術集会抄録集  2023.3  (一社)日本循環器学会

    　More details

    Language：English  

  • 光吉 こころ, 窪田 佳代子, 赤尾 光優, 宮永 直, 大石 充   肺動脈性肺高血圧症における最大呼気流速と予後に関する検討  

    日本心臓病学会学術集会抄録  2025.9  (一社)日本心臓病学会

    　More details

    Language：Japanese  

  • 光吉 こころ, 窪田 佳代子, 宮永 直, 赤尾 光優, 大石 充   Efficacy of Pulmonary Vasodilators for Pulmonary Hypertension Associated with Lung Diseases(タイトル和訳中)  

    日本循環器学会学術集会抄録集  2025.3  (一社)日本循環器学会

    　More details

    Language：English  

  • 光吉 こころ, 赤尾 光優, 宮永 直, 窪田 佳代子, 大石 充   CTEPHにおけるDダイマーと重症度との関連性  

    日本肺高血圧・肺循環学会学術集会抄録集  2023.6  日本肺高血圧・肺循環学会

    　More details

    Language：Japanese  

  • 赤尾 光優, 宮永 直, 窪田 佳代子, 大石 充   CPFE-severe PHに対しupfront combination therapyを行った一例  

    日本肺高血圧・肺循環学会学術集会・日本小児肺循環研究会プログラム・抄録集  2022.7  日本肺高血圧・肺循環学会・日本小児肺循環研究会

    　More details

    Language：Japanese  

  • 宮永 直, 光吉 こころ, 赤尾 光優, 窪田 佳代子, 大石 充   3群PHに対する当院での治療成績  

    日本肺高血圧・肺循環学会学術集会抄録集  2024.8  日本肺高血圧・肺循環学会

    　More details

    Language：Japanese  

▼display all

Awards

  • 第124回 日本循環器学会九州地方会　YIA臨床研究 (CR) セッション 最優秀賞

    2018.6   膠原病患者における運動誘発性肺高血圧症の非侵襲的予測因子の検討